Price (delayed)
$0.1928
Market cap
$3.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.97
Enterprise value
$6.52M
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics
There are no recent dividends present for APTO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.